Back to Awarded Treatment Trials
Awarded Trial: 00-029
Grant ID
00-029
Illness
Schizophrenia
Primary Drug/Intervention
D-serine
Primary Dosage
30 mg/kg/day
Secondary Drug Intervention
N/A
Secondary Dosage
N/A
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Heresco-Levy
Sample Size
39
Duration of Study Period for Each Subject
6 weeks
Outcome Measurements
PANSS, BPRS
Results
D-serine treatment was associated with significant improvements in negative, positive and depressive symptoms.
Publication
Heresco-Levy U, Javitt DC, Ebstein R, Vass A, Lichtenberg P, Bar G, Catinari S, Ermilov M. D-serine efficacy as add-on pharmacotherapy to risperidone and olazapine for treatment-refractory schizophrenia. Biol Psychiatry. 2005;57:577-585.
Link
http://www.ncbi.nlm.nih.gov/pubmed/15780844
PI Name
Uriel Heresco-Levy
Degree
MD
Center
N/A
Institution
Ezrath Nashim - Herzog Memorial Hospital
Address
P.O. Box 35300
City or Town
Jerusalem
State or Province
N/A
Zip or Postal Code
91351
Country
Israel
Email Address
heresco@md2.huji.ac.il